Skip to main content
. 2002 Oct;76(20):10465–10472. doi: 10.1128/JVI.76.20.10465-10472.2002

FIG. 5.

FIG. 5.

FTI-277 inhibits production of HDV genotype III genome-containing particles. (A) Following transfection with both HDV genotype III and HBV genome-encoding constructs, as described in Fig. 1 and in Materials and Methods, Huh7 cells were maintained in a daily changed medium containing carrier (0.22% DMSO and 400 μM DTT) alone (lanes 2 and 8) or carrier plus 0.1 μM (lanes 3 and 9), 0.5 μM (lanes 4 and 10), 1 μM (lanes 5 and 11), or 5 μM (lanes 6 and 12) FTI-277. On day 10 after transfection, cells (lanes 1 to 6) and supernatants (lanes 7 to 12) were processed for Northern analysis of HDV RNA, as described in Materials and Methods. Lanes 1 and 7 correspond to nontransfected cells subjected to carrier-containing medium. MW markers are indicated at the left of the figure. (B) HDV RNA in the culture medium of cells treated with the indicated amounts of FTI-277 was quantitated using a phosphorimager and plotted as a percentage of the no-drug control (0 μM) (black bars). Also shown are the results from total RNA quantitation (Total RNA) (grey bars) and HBV surface antigen synthesis and secretion (HBsAg) (empty bars).